When a course of hepatitis C treatment costs $84,000 in the United States and under $100 in India, the difference is not charity. It is architecture — a deliberate system of price controls, competitive manufacturing, and scale that has made India the world’s most important source of affordable medicine.
India’s low drug prices are not an accident. They are the product of three interlocking forces: government price regulation, a uniquely competitive generics market, and a patent law history that seeded one of the world’s largest pharmaceutical manufacturing ecosystems.
The result: India supplies 20% of the world’s generic medicines by volume, 60% of global vaccine demand, and nearly 50% of Africa’s generic medicines — at prices that are often a fraction of what patients pay elsewhere.
The National Pharmaceutical Pricing Authority (NPPA), established in 1997 under the Department of Pharmaceuticals, enforces ceiling prices on scheduled medicines through the Drugs (Prices Control) Order, 2013. Any drug on the National List of Essential Medicines (NLEM) automatically comes under price control.
The NLEM 2022 — the most recent revision — covers 384 drugs across 27 therapeutic categories. The NPPA sets ceiling prices using a market-based formula: the simple average price of all brands with more than 1% market share. Annual price increases are capped to the Wholesale Price Index — just 1.74% in the April 2025 revision.
India’s pharmaceutical industry comprises more than 3,000 companies operating approximately 10,500 manufacturing units, producing over 60,000 generic brands across nearly 60 therapeutic areas. This density of competition — unmatched anywhere in the world — drives prices down through market forces alone, independent of regulation.
Production costs are approximately 60% lower than the United States and roughly half those of Europe, a structural advantage rooted in India’s engineering workforce, lower land and labour costs, and decades of accumulated pharmaceutical manufacturing expertise.
India’s 1970 Patents Act permitted process patents only — not product patents. For 35 years, Indian companies could legally reverse-engineer any drug and manufacture it through a different process. This created the conditions for a massive generics ecosystem to develop.
When India reintroduced product patents in 2005 under WTO/TRIPS obligations, the industry was already the largest generics manufacturer in the world. The ecosystem was self-sustaining: 650+ US FDA-approved manufacturing plants, 2,000+ WHO-GMP certified facilities, and a global reputation for quality at scale.
Abstract policy becomes concrete at the pharmacy counter. These are documented price comparisons for specific drugs — not aggregated averages, but verifiable figures from published sources.
| Drug | US Price | India Price | Condition |
|---|---|---|---|
| Sofosbuvir (Sovaldi) | $84,000 | $50–$539 | Hepatitis C (12-week cure) |
| Biktarvy (HIV) | $4,216/month | ~$150/month | HIV antiretroviral |
| EFV/TDF/3TC | Thousands/year | ~$100/year | Standard HIV regimen |
| Atorvastatin 10mg | ~$173/month | $0.50–$2/month | Cholesterol (statin) |
India’s pricing architecture is not a domestic story. It is the reason much of the developing world has access to essential medicines at all.
India supplies approximately 40% of all generic drugs used in the United States, making it the largest single source of generics for the American market. In sub-Saharan Africa, nearly 50% of all medicines come from Indian manufacturers. And India produces 4–5 billion vaccine doses annually — more than any other country — supplying 60% of global vaccine demand.
The Serum Institute of India alone manufactures 1.5 billion vaccine doses per year. During the COVID-19 pandemic, India’s manufacturing capacity was the backbone of global vaccine distribution to low- and middle-income countries.